Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vespireit vs Arlevert in Autonomic Dysfunction with Functional Vertigo
NCT06321341Phase 4Recruiting
- Sponsor
- Valenta Pharm
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of buspirone in autonomic dysfunction, Persistent Postural-Perceptual Dizziness (PPPD), sponsored by Valenta Pharm. Started Jan 2024; status: recruiting.
02
Drugs
buspirone
03
Conditions
autonomic dysfunctionPersistent Postural-Perceptual Dizziness (PPPD)
Beyond the preview
Go deeper on NCT06321341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321341.